Company intelligence / Profile preview

Tasgen Bio

China

Ownership: Private
Development stage: Other

Overview

Tasgen Bio is described as a clinical-stage biologics developer working on half-life extended bio-better drugs; public information focuses on its platform rather than specific trial outcomes, and detailed clinical results are not disclosed in accessible sources.

Modalities: BiologicProtein
Industry: Biotech

Partnerships

Tasly PharmaceuticalsGenexine

Beyond the preview

Go deeper on Tasgen Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tasgen Bio.

Explore the full profile